文献速递临床生化质量管理与危急值

生物学变异数据关键评估清单:评估生物学变异研究的标准

The Biological Variation Data Critical Appraisal Checklist: A Standard for Evaluating Studies on Biological Variation.
PubMed 文献 · Clin Chem · 2017-12-08

欧洲临床化学与检验医学联合会工作组制定BIVAC清单,从研究设计、方法和统计处理三方面对生物学变异文献进行质量分级(A-D级)。对28个检测项目的128篇文献共935个估计值进行评估,9%为D级,超过60%的847个案例中离群值分析和方差齐性检验仅达C级。荟萃分析得出丙氨酸氨基转移酶(ALT)的个体内生物学变异(CVI)估计值为15.4%。

要点

  • BIVAC清单包含14个质量条目,评估研究设计、方法和统计处理
  • D级研究提供的生物学变异估计值不应应用于临床实践
  • 离群值分析和方差齐性检验是常见薄弱环节,超60%案例仅达C级

核心结论

  • 应用BIVAC评估生物学变异文献发现研究细节和统计分析的不足,影响估计值的真实性。
  • 符合BIVAC的研究数据可合并产生稳健的全局估计值,用于安全临床实践。

研究设计与样本

  • 欧洲临床化学与检验医学联合会工作组制定BIVAC清单,对28个检测项目的文献进行系统检索和评估。
  • 共纳入128篇出版物,提供935个不同的生物学变异估计值。

主要发现

  • 9%的出版物获得D级评分。
  • 超过60%的847个案例中,离群值分析和方差齐性检验被评为C级。
  • 荟萃分析得出ALT的CVI估计值为15.4%。

关键数值与推荐

  • BIVAC将出版物评为A、B、C或D级,表示对14个质量条目的依从性递减。
  • D级表示相关的生物学变异估计值不应在临床实践中应用。

临床怎么用

  • 临床实验室应优先采用BIVAC评级较高(A-C级)的生物学变异数据。
  • D级研究的生物学变异数据不宜用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concern has been raised about the quality of available biological variation (BV) estimates and the effect of their application in clinical practice. A European Federation of Clinical Chemistry and Laboratory Medicine Task and Finish Group has addressed this issue. The aim of this report is to (a) describe the Biological Variation Data Critical Appraisal Checklist (BIVAC), which verifies whether publications have included all essential elements that may impact the veracity of associated BV estimates, (b) use the BIVAC to critically appraise existing BV publications on enzymes, lipids, kidney, and diabetes-related measurands, and (c) apply metaanalysis to deliver a global within-subject BV (CVI) estimate for alanine aminotransferase (ALT). METHODS: In the BIVAC, publications were rated as A, B, C, or D, indicating descending compliance for 14 BIVAC quality items, focusing on study design, methodology, and statistical handling. A D grade indicated that associated BV estimates should not be applied in clinical practice. Systematic searches were applied to identify BV studies for 28 different measurands. RESULTS: In total, 128 publications were identified, providing 935 different BV estimates. Nine percent achieved D scores. Outlier analysis and variance homogeneity testing were scored as C in >60% of 847 cases. Metaanalysis delivered a CVI estimate for ALT of 15.4%. CONCLUSIONS: Application of BIVAC to BV publications identified deficiencies in required study detail and delivery, especially for statistical analysis. Those deficiencies impact the veracity of BV estimates. BV data from BIVAC-compliant studies can be combined to deliver robust global estimates for safe clinical application.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Aarsand AK, Røraas T, Fernandez-Calle P, et al. The Biological Variation Data Critical Appraisal Checklist: A Standard for Evaluating Studies on Biological Variation. Clin Chem. 2017. PMID: 29222339. doi:10.1373/clinchem.2017.281808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。